Serial liver transaminases have no prognostic value in non-alcoholic fatty liver disease.

fatty liver disease liver enzymes natural history

Journal

Canadian liver journal
ISSN: 2561-4444
Titre abrégé: Can Liver J
Pays: Canada
ID NLM: 101778326

Informations de publication

Date de publication:
2019
Historique:
received: 04 04 2018
accepted: 07 04 2018
entrez: 22 8 2022
pubmed: 25 2 2019
medline: 25 2 2019
Statut: epublish

Résumé

Routine measurement of liver transaminases is common in the general monitoring of patients with non-alcoholic fatty liver disease (NAFLD), but there is little data to support the utility of this practice. The aims of this study were to determine how alanine aminotransferase (ALT) results vary over time in patients with NAFLD; and to determine if serial measurement of ALT is a useful clinical marker for progression of NAFLD. Consecutive adult patients with NAFLD were followed prospectively in a tertiary liver disease clinic over a 15-year period. Clinicodemographic characteristics and the change in liver enzymes, liver function, and histopathology were followed over time. Paired A change in liver transaminases over time is not a useful metric in predicting outcomes in patients with NAFLD. Additionally, all stages of NAFLD are equally responsive to standard medical interventions of advocating for weight loss and correcting metabolic disturbances.

Sections du résumé

Background UNASSIGNED
Routine measurement of liver transaminases is common in the general monitoring of patients with non-alcoholic fatty liver disease (NAFLD), but there is little data to support the utility of this practice. The aims of this study were to determine how alanine aminotransferase (ALT) results vary over time in patients with NAFLD; and to determine if serial measurement of ALT is a useful clinical marker for progression of NAFLD.
Methods UNASSIGNED
Consecutive adult patients with NAFLD were followed prospectively in a tertiary liver disease clinic over a 15-year period. Clinicodemographic characteristics and the change in liver enzymes, liver function, and histopathology were followed over time. Paired
Results/Conclusion UNASSIGNED
A change in liver transaminases over time is not a useful metric in predicting outcomes in patients with NAFLD. Additionally, all stages of NAFLD are equally responsive to standard medical interventions of advocating for weight loss and correcting metabolic disturbances.

Identifiants

pubmed: 35991834
doi: 10.3138/canlivj.2018-0006
pmc: PMC9202679
doi:

Types de publication

Journal Article

Langues

eng

Pagination

19-22

Informations de copyright

Copyright © 2019 Canadian Association for the Study of the Liver.

Déclaration de conflit d'intérêts

The authors have nothing to disclose.

Références

J Gastrointestin Liver Dis. 2012 Mar;21(1):53-8
pubmed: 22457860
JAMA. 2012 Feb 22;307(8):832-842
pubmed: 22357834
BMJ. 2011 Nov 18;343:d6891
pubmed: 22102439
Liver Int. 2011 May;31(5):730-9
pubmed: 21457446
Gastroenterology. 2005 Jun;128(7):1898-906
pubmed: 15940625
Aliment Pharmacol Ther. 2011 Jun;33(12):1350-60
pubmed: 21517924
QJM. 2012 May;105(5):425-32
pubmed: 22156706

Auteurs

Julia Uhanova (J)

Section of Hepatology, John Buhler Research Centre, University of Manitoba, Winnipeg, Manitoba.

Gerald Minuk (G)

Section of Hepatology, John Buhler Research Centre, University of Manitoba, Winnipeg, Manitoba.

Kamila Premji (K)

Division of Gastroenterology, Multi-Organ Transplant Program, University of Western Ontario, London, Ontario.

Natasha Chandok (N)

Section of Hepatology, John Buhler Research Centre, University of Manitoba, Winnipeg, Manitoba.
Division of Gastroenterology, Multi-Organ Transplant Program, University of Western Ontario, London, Ontario.
Department of Medicine, William Osler Health Centre, Brampton, Ontario.

Classifications MeSH